Biomarkers of Gemtuzumab Ozogamicin Response for Acute Myeloid Leukemia Treatment

Biomarkers of Gemtuzumab Ozogamicin Response for Acute Myeloid Leukemia Treatment

Gemtuzumab ozogamicin (GO, Mylotarg<sup>®</sup>) consists of a humanized CD33-targeted antibody-drug conjugated to a calicheamicin derivative. Growing evidence of GO efficacy in acute myeloid leukemia (AML), demonstrated by improved outcomes in CD33-positive AML patients across phase I t...

Full description

Bibliographic Details
Main Authors: Laurène Fenwarth, Elise Fournier, Meyling Cheok, Thomas Boyer, Fanny Gonzales, Sylvie Castaigne, Nicolas Boissel, Juliette Lambert, Hervé Dombret, Claude Preudhomme, Nicolas Duployez
Format: Article
Language:English
Published: MDPI AG 2020-08-01
Series:International Journal of Molecular Sciences
Subjects:
acute myeloid leukemia
gemtuzumab ozogamicin
biomarkers
CD33
FLT3
therapy
Online Access:https://www.mdpi.com/1422-0067/21/16/5626

Internet

https://www.mdpi.com/1422-0067/21/16/5626

Similar Items